文献速递肝病消化道肿瘤与早癌

血清代谢组学特征可预测早期肝细胞癌切除或消融后肿瘤复发

Research Communication: Serum Metabolomic Signatures Predict Tumour Recurrence After Resection or Ablation in Patients With Early-Stage Hepatocellular Carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2025-08-26

该研究在78例经手术切除或局部消融后达到完全缓解的早期肝细胞癌患者中,验证了6种和13种代谢物特征对复发的预测价值。中位随访期间32例(41.0%)死亡、40例(51.3%)复发,其中35例(87.5%)为早期复发。多变量分析显示6种代谢物特征与早期复发相关(aHR 2.8,95%CI 1.1-7.5),13种代谢物特征与总体复发相关(aHR 2.5,95%CI 1.1-6.0)。

要点

  • 6种代谢物特征与早期复发独立相关(aHR 2.8,95%CI 1.1-7.5)。
  • 13种代谢物特征与总体复发独立相关(aHR 2.5,95%CI 1.1-6.0)。
  • 血清代谢物有助早期肝癌治疗后复发风险分层。

核心结论

  • 血清代谢组学特征可能用于早期肝细胞癌切除或消融后的复发风险分层。

研究设计与样本

  • 在78例经手术切除或局部消融后达到完全缓解的早期肝细胞癌患者中验证6种和13种代谢物特征。

主要发现

  • 78例中32例(41.0%)死亡,40例(51.3%)复发,复发者中35例(87.5%)为早期复发。
  • 多变量分析中6种代谢物特征与早期复发相关(aHR 2.8,95%CI 1.1-7.5)。
  • 13种代谢物特征与总体复发相关(aHR 2.5,95%CI 1.1-6.0)。

临床怎么用

  • 对达到完全缓解的早期肝细胞癌患者,可考虑结合血清代谢物特征评估复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with hepatocellular carcinoma (HCC) often experience recurrence after curative therapies, underscoring a need for risk stratification models. We validated 6 and 13-metabolite signatures in patients who achieved complete response following surgical resection or local ablation. Of 78 patients, 32 (41.0%) died and 40 (51.3%) experienced recurrence, of whom 35 (87.5%) had early recurrence. In multivariable analysis, the 6-metabolite signature was associated with early recurrence (aHR 2.8, 95% CI 1.1-7.5), and the 13-metabolite signature was associated with overall recurrence (aHR 2.5, 95% CI 1.1-6.0). These data support the potential role of serum metabolites in post-treatment risk stratification for HCC recurrence.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Arvind A, Kanzaki H, Ahmed F, et al. Research Communication: Serum Metabolomic Signatures Predict Tumour Recurrence After Resection or Ablation in Patients With Early-Stage Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2025. PMID: 40875577. doi:10.1111/apt.70355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。